IOL power calculations for cataract surgery have come a long way since the days of empiric regression formulae such as the SRK and SRK II. We now tend to use theoretical methods such as the Holladay, SRK/T, Hoffer Q and Haigis, among others. While we t…
As the 2014 Ebola epidemic in West Africa wanes, the largest number of survivors of an Ebola outbreak in history are left in its wake, with ocular complications persisting through convalescence and forcing a demand for better understanding of the lingering effects of the virus.Chronic pain, headaches and eye problems such as eye pain, eye redness and blurred vision are some of the “post-Ebola syndrome” symptoms seen among survivors in West Africa.
Iris fixation and scleral fixation of dislocated IOLs had similar visual outcomes, but iris fixation was associated with more postoperative inflammation and less stable refraction, according to a study in South Korea.“The iris fixation techniques for the repositioning of dislocated IOL showed similar efficacy to the scleral fixation. However, despite iris fixation having the advantage of shorter operation time, it had several drawbacks, including increased rates of induced astigmatism and immediate postoperative inflammation, as well as earlier recurrence and less stable refraction,” Kyeong Hwan Kim, MD, the first author, told (Read more...)
A 53-year-old HIV-positive man was admitted to Tufts Medical Center for 3 days of worsening periocular pain and blurred vision in his left eye.Initially, he noticed mild swelling of the left upper eyelid associated with an ipsilateral aching pain when he looked in left lateral gaze. As the pain worsened, he also noticed blurred vision in the left eye. He denied sinusitis or symptoms of an upper respiratory infection, nasal or ocular discharge, diplopia or headaches. He also noted that for the last “few days” he had “not felt well,” (Read more...)
In just a short couple of weeks, we will convene en masse in Las Vegas for our annual shindig, the American Academy of Ophthalmology annual meeting. As usual, we will be buying stuff and selling ourselves, and the hot topic is going to be dry eye. Seriously, hotter than femtosecond laser-assisted cataract surgery! Even more than that, being a dry eye doc is going be cool; who doesn’t want to be cool?Admit it: You would like to be cool.
Having initiated its fourth phase 3 trial for Rhopressa and its first phase 3 registration trial for Roclatan, Aerie pharmaceuticals is heading into 2016 with the intention of filing a new drug application for Rhopressa and beginning two more phase 3 t…